Skip to main content
HR 1537 114th Congress House

Advancing Hope Act of 2015

Official title: To amend the Federal Food, Drug, and Cosmetic Act to reauthorize a program of priority review to encourage treatments for rare pediatric diseases, and for other purposes.

Introduced: March 23, 2015 See on congress.gov
Health Blood and blood diseasesCancerChild healthDrug safety, medical device, and laboratory regulation
More subjectsShow fewer subjects
Drug therapyHereditary and development disordersInfectious and parasitic diseasesWorld health
Sign in to write a letter Sign in to watch
This bill died when the 114th Congress ended
It never became law before the 114th Congress (2015–2016) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 27, 2015
Referred to the Subcommittee on Health.
Mar 23, 2015
Referred to the House Committee on Energy and Commerce.
Mar 23, 2015
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action March 27, 2015

Referred to the Subcommittee on Health.

 Plain-English summary Congressional Research Service

Advancing Hope Act of 2015

This bill amends the Federal Food, Drug, and Cosmetic Act to expand the priority review voucher program for rare pediatric diseases to include treatments for sickle cell disease and pediatric cancers.

The voucher program is extended by removing the provision terminating the program one year after the Food and Drug Administration's (FDA's) issuance of three rare pediatric disease vouchers.

A voucher may not be issued for a rare pediatric disease product if a voucher was issued for the product as a tropical disease product.

A tropical disease voucher may not be issued for a product that was approved, over two years before submitting an application to the FDA, for commercial marketing by a foreign government to treat a tropical disease.
 Related & companion bills 1
  • S 1878 Related bill Advancing Hope Act of 2016
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
 Cosponsors 5
All 5 Democratic 2 Republican 3
R
Bilirakis, Gus M.
Florida · Apr 28, 2015
 D
Cohen, Steve
Tennessee · Mar 23, 2015
 R
Kelly, Mike
Pennsylvania · Mar 23, 2015
 R
McCaul, Michael T.
Texas · Mar 23, 2015
 D
Van Hollen, Chris
Maryland · Mar 23, 2015
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 1537: Advancing Hope Act of 2015. 114th Congress. Open America. https://openamerica.io/bill/114-HR-1537/
MLA
"H.R. 1537: Advancing Hope Act of 2015." 114th Congress, 2026, Open America, https://openamerica.io/bill/114-HR-1537/.
Bluebook (legal)
H.R. 1537, 114th Cong. (2026), https://openamerica.io/bill/114-HR-1537/.
Markdown link
[H.R. 1537: Advancing Hope Act of 2015](https://openamerica.io/bill/114-HR-1537/)
Report a problem